Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|November 15, 2017
- Pharmaceutical Technology-11-15-2017
- Volume 2017 ebook
- Issue 2
Therapeutic Vaccines Target Cancer and Other Viral-Induced Diseases
Author(s)Feliza Mirasol
The use of therapeutic vaccines presents a new way to manage diseases, such as cancer and sexually transmitted diseases.
Advertisement
As research into harnessing the immune system's natural ability to fight disease advances, so does the development of therapeutic vaccines. Much of the attention in therapeutic vaccine R&D is aimed at targeted therapies for cancer, but substantial research is also going into therapeutic vaccines for other indications, including sexually transmitted diseases.
Download the
.
Article Details
Pharmaceutical Technology and BioPharm International
eBook: Vaccine Development and Manufacturing 2017
November 2017
Pages: 20–24
Citation
When referring to this article, please cite it as F. Mirasol, "Therapeutic Vaccines Target Cancer and Other Viral-Induced Diseases," Pharmaceutical Technology and BioPharm International Vaccine Development and Manufacturing 2017 eBook (November 2017).
Articles in this issue
almost 9 years ago
Designing and Operating Flexible, High-Containment Vaccine Manufacturingalmost 9 years ago
Using Human Challenge Trials to Develop Flu Vaccinesalmost 9 years ago
Making Vaccines Accessiblealmost 9 years ago
Moving to Closed Systems for Aseptic Processingalmost 9 years ago
Cold Chain: Delivering Vaccines to Patientsalmost 9 years ago
Accelerating Vaccine Development and ManufacturingAdvertisement
Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
Complying with International Pharmacopoeias
4
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
5